Having this in mind, we addressed SLC5A5 expression by qPCR and NIS expression by IHC analysis, in a large series of primary thyroid carcinomas and looked for possible associations with some clinicopathological and molecular features, as well as to the response to RAI therapy and outcome. In order to validate our results of SLC5A5 mRNA expression associations’ with clinicopathological and molecular features and also to get new evidences, we used the data available about SLC5A5 in TCGA Research Network that completed an integrated genomic analysis of 496 PTCs using NGS and other pan-genomic technologies, together with detailed pathologic and clinical data (30).